TRICARE expands coverage of investigational drugs

December 11, 2020

Effective September 30, 2020, TRICARE has expanded coverage for the use of investigational drugs to treat serious or life-threatening cases of COVID-19 infection or its associated sequelae. The drugs must be approved by the US Food and Drug Administration (FDA) and administered in an FDA-approved setting.